^
Association details:
Biomarker:KMT5C deletion
Cancer:Non Small Cell Lung Cancer
Drug:erlotinib (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510

Published date:
03/18/2020
Excerpt:
The findings from this study identified an epigenetic factor, SUV420H2 that when lost drives resistance of NSCLC to multiple EGFRi, including erlotinib, gefitinib, afatinib, and osimertinib.